Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
Conditions
Squamous Cell Carcinoma of the Head and Neck
Conditions: official terms
Carcinoma, Squamous Cell - Head and Neck Neoplasms
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Intervention
Name: Cisplatin Type: Drug
Name: Radiotherapy Type: Radiation
Name: Debio 1143 Type: Drug
Name: Placebo Type: Drug
Overall Status
Recruiting
Summary
The use of multiple drugs in a single clinical trial or as a therapeutic strategy has become common, particularly in the treatment of cancer. Because traditional trials are designed to evaluate one agent at a time, the evaluation of therapies in combination requires specialized trial designs. In place of the traditional separate phase I and II trials, this trial uses a single phase I/II clinical trial to evaluate simultaneously the safety and efficacy of combination dose levels, and select the optimal combination dose.

Therefore, this is a two part trial of Debio 1143 combined with concurrent cisplatin and radiotherapy (CRT) in participants with previously untreated stage III, IVa or IVb head and neck cancer. The trial begins with an initial period of dose escalation (Phase I) to investigate the maximum tolerated dose (MTD) of Debio 1143 that can safely be given in combination with CRT.

Using the MTD determined in the Phase I portion, the randomized phase II trial in 94 participants compares Debio 1143 to placebo, both with concomitant CRT. The aims are to evaluate the efficacy and safety of Debio 1143, while exploring biomarkers, Debio 1143 pharmacokinetics, and pharmacokinetic/ pharmacodynamic relationships.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Meets protocol-specified criteria for qualification and contraception

- Is willing and able to comply with study procedures and restrictions related to food, drink and medications

- Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures

Exclusion Criteria:

- Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters

- Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

1. the safety or well-being of the participant or study staff;

2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);

3. the analysis of results
Locations
Institut Curie
Paris, France
Status: Recruiting
Institut Claudius Regaud
Toulouse, France
Status: Active, not recruiting
Institut Gustave Roussy
Villejuif, France
Status: Recruiting
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
Status: Recruiting
Start Date
October 2013
Completion Date
October 2018
Sponsors
Debiopharm International SA
Source
Debiopharm International SA
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page